Tradestie Institutional Equity Comparison Engine
DCTH vs CRMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while DCTH counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DCTH trades at N/M Forward P/E with 5.2% operating margin (+70.7% YoY revenue) versus CRMD at 49.0x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, DCTH sits in BREAKOUT (43rd %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
DCTH N/M vs CRMD 49.0x Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 5.2% vs 41.0% ยท YoY +70.7% vs -47.7%
Momentum & Technical Winner
DCTH
1Y +128.6% vs -56.2% ยท 52W Pos 80% vs 3%
Options & Structure Winner
DCTH
BREAKOUT (43rd %ile IV) vs BREAKDOWN (25th %ile IV)
DCTH
NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap
$743.8M
1M Return
+39.77%
1Y Return
+128.57%
Forward P/E
N/M
Unified AI Score
35.9 / 100
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap
$384.7M
1M Return
-32.3%
1Y Return
-56.16%
Forward P/E
49.0x
Unified AI Score
53.2 / 100
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DCTH +128.57%
CRMD -56.16%
Spread: +184.73 pp (DCTH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | CRMD Revenue | DCTH Op. Margin | CRMD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -6250.4% | CRMD |
| FY2019 | N/A | $0M | N/A | -7416.3% | CRMD |
| FY2020 | N/A | $0M | N/A | -11378.4% | CRMD |
| FY2021 | $0M | $0M | -690.0% | -15417.5% | DCTH |
| FY2022 | $0M | $0M | -1245.1% | -46819.9% | DCTH |
| FY2023 | $0M | N/A | -1849.0% | N/A | DCTH |
| FY2024 | $40M | $40M | -33.4% | -51.4% | DCTH |
| FY2025 | $90M | $310M | 0.8% | 48.2% | CRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DCTH | CRMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $743.8M | $384.7M | Larger Scale | DCTH |
| Trailing P/E Ratio Valuation | 133.6x | 2.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | N/M | 49.0x | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | +70.7% | -47.7% | Higher Growth | DCTH |
| Operating Margin (TTM) Profitability | 5.2% | 41.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 6.0% | 15.5% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 5.4% | 15.3% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 80% ($8โ$23) | 3% ($5โ$13) | Stronger Trend | DCTH |
| Beta / 30D Volatility Risk Regime | 1.63ฮฒ ยท 131% Vol | 1.20ฮฒ ยท 107% Vol | Lower Realized Risk | CRMD |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 53.2 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DCTH vs CRMD Buy Guide
DCTH
BREAKOUT
66d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
43rd %ile
IV Regime
Balanced (25thโ60th %ile)
CRMD
BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DCTH nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.